<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294524</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A03169-44</org_study_id>
    <secondary_id>2017-A03169-44</secondary_id>
    <nct_id>NCT04294524</nct_id>
  </id_info>
  <brief_title>Management of Sleep Apnoea Syndrome (SAS) in Patients With Vasovagal Syncope (VVS)</brief_title>
  <acronym>VVS-SAS</acronym>
  <official_title>Management of Sleep Apnoea Syndrome (SAS) in Patients With Vasovagal Syncope (VVS): a Protocol for the VVS-SAS Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PEAS (Pole d'Exploration des Apnees du Sommeil)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PEAS (Pole d'Exploration des Apnees du Sommeil)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, registry-based study whose primary objective is to evaluate the
      effect of treatment for sleep apnoea syndrome (SAS) on the number of syncope/malaise episodes
      in a population suffering from both idiopathic, recurrent vasovagal syncope/malaises and SAS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment for sleep apnoea syndrome includes continuous positive airway pressure (CPAP) or a
      mandibular advancement device (MAD). Additional routine follow-up includes 24 hour holter
      monitoring on a yearly basis, polysomnography on a yearly basis, multiple sleep latency
      tests, table tilt tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">February 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-month syncope rate</measure>
    <time_frame>Month -6 to Day 0 versus Months +6 to +12</time_frame>
    <description>Day 0 refers to the initiation of sleep apnea treatment. The baseline syncope rate refers to syncope events occurring between month -6 and day 0 (S_before). The post-treatment syncope rate refers to syncope events occurring between months +6 and +12(S_after). The change is rates is S_before minus S_after.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Syncope/malaise dates</measure>
    <time_frame>Day 0 to Month 12</time_frame>
    <description>Dates of syncopes/malaises throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported syncope/malaise frequency</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>never, rare, every three months, every month, every week, several times per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported syncope/malaise frequency</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>never, rare, every three months, every month, every week, several times per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported position of syncopes/malaises</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>standing, sitting, lying down</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported position of syncopes/malaises</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>standing, sitting, lying down</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported sycope/malaise trigger</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>heat, crowding, pain, stress, effort, lack of sleep, none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported sycope/malaise trigger</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>heat, crowding, pain, stress, effort, lack of sleep, none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported sycope/malaise timing</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>diurnal, nocturnal, postprandial, peri/post-miction/defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported sycope/malaise timing</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>diurnal, nocturnal, postprandial, peri/post-miction/defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported frequency of signs preceding a loss of consciousness</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>always, sometimes, never</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported frequency of signs preceding a loss of consciousness</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>always, sometimes, never</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for snoring</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for snoring</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nocturnal agitation</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nocturnal agitation</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for restless legs</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for restless legs</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nycturia</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nycturia</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for morning headaches</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for morning headaches</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for absence of libido</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for absence of libido</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nocturnal sweating</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for nocturnal sweating</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for gastro-oesophagien reflux</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for gastro-oesophagien reflux</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for palpitations</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for palpitations</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for lack of concentration while driving</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for lack of concentration while driving</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>Visual analogue scale (VAS) ranging from 0 (no symptoms) to 10 (strongest symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-item Impact of Syncope on Quality of Life (ISQL) questionnaire</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>The ISQL has a possible range from 0 to 55. Higher scores indicate stronger impact of syncope on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-item Impact of Syncope on Quality of Life (ISQL) questionnaire</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>The ISQL has a possible range from 0 to 55. Higher scores indicate stronger impact of syncope on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Epworth Sleepiness Scale</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This questionnaire describes sleepiness with a score that ranges from 0 to 24. Higher scores indicate more sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Epworth Sleepiness Scale</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>This questionnaire describes sleepiness with a score that ranges from 0 to 24. Higher scores indicate more sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pichot's fatigue scale</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This scale describes fatigue and ranges from 0 to 32. Higher scores indicate more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pichot's fatigue scale</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>This scale describes fatigue and ranges from 0 to 32. Higher scores indicate more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pichot's depression inventory</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This scale ranges from 0 to 13. Higher scores indicate more elements of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pichot's depression inventory</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>This scale ranges from 0 to 13. Higher scores indicate more elements of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire (the Medical Outcome Study - Short Form (SF36))</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>The SF36 ranges from 0 to 100. Higher scores indicate higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life questionnaire (the Medical Outcome Study - Short Form (SF36))</measure>
    <time_frame>Yearly visit (month 12)</time_frame>
    <description>The SF36 ranges from 0 to 100. Higher scores indicate higher quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The presence/absence of retrognathia</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This is a binary variable indicating qualitative presence or absence of a particular condition.</description>
  </other_outcome>
  <other_outcome>
    <measure>The presence/absence of archival palate</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This is a binary variable indicating qualitative presence or absence of a particular condition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mallampati score</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The presence/absence of anterior open bite</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This is a binary variable indicating qualitative presence or absence of a particular condition.</description>
  </other_outcome>
  <other_outcome>
    <measure>The presence/absence of cervico-mental angle blunting</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This is a binary variable indicating qualitative presence or absence of a particular condition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index (kg/m2)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal circumference (cm)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic blood pressure (mmHg) while lying down</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic blood pressure (mmHg) while lying down after having remained in a standing position for 3 minutes</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic blood pressure (mmHg) while lying down</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic blood pressure (mmHg) after having remained in a standing position for 3 minutes</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulse (beats per minute) while lying down</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulse (beats per minute) after having remained in a standing position for 3 minutes</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence/absence of a positive table tilt test</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <description>This is a binary variable indicating qualitative presence or absence of a particular condition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Haemoglobin (g/dl)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Haematocrit (%)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood thyroid stimulating hormone (microU/l)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood sodium levels (mmol/l)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood potassium levels (mmol/l)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Morning cortisol (mmol/l at 8 am)</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Syncope, Vasovagal</condition>
  <condition>Sleep Apnea Syndromes</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleep apnea treatment</intervention_name>
    <description>Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The targeted study population consists of consecutive patients with both vasovagal syncope
        and sleep apnea syndrome with an indication for treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obstructive sleep apnoea syndrome (&gt;15 respiratory micro awakenings per hour of sleep)
             with an indication for treatment

          -  Recurring vasovagal syncope episodes defined as follows: at least three vasovagal
             syncopes during the last two years - OR- symptoms of orthostatic intolerance occurring
             in the last 6 months (Symptoms are triggered by orthostatism and can include malaises
             without loss of consciousness, asthenia, dizziness, visual disturbances, tinnitus,
             palpitations, headache, limitations of physical activity)

        Exclusion Criteria:

          -  Pathology that may explain syncope symptoms

          -  Cardiopathy

          -  Known disautonomia

          -  Hypotension of known origin

          -  Adrenal insufficiency

          -  Thyroid disorder

          -  History of sudden death in a first degree family member
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Puel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pôle d'exploration des apnées su sommeil (PEAS), Nouvelle Clinique Bel-Air - Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Puel, MD</last_name>
    <phone>+33 557810587</phone>
    <email>vpuel001@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Godard, MD</last_name>
    <email>illa.godard05@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals of Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric Gagnadou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Bel Air</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Puel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Godard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georgios Papaioannou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Gosse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Louis Pépin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Bouchard</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice Thoin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Public Assistance - Hospitals of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Claude Deharo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric Roche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Grace Hospital</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naïma Zarqane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>PEAS (Pole d'Exploration des Apnees du Sommeil)</investigator_affiliation>
    <investigator_full_name>Vincent Puel</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

